Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Mol Immunol ; 17(2): 153-162, 2020 02.
Article in English | MEDLINE | ID: mdl-30552382

ABSTRACT

Classical signaling lymphocyte activating molecule (SLAM) family receptors are abundant within many types of immune cells, whereas the nonclassical SLAM family receptors SLAMF8 and SLAMF9, which uniquely lack cytoplasmic signaling motifs, are highly expressed by myeloid cells. Due to the potential redundancy, whether these two receptors regulate macrophage function remains largely unknown. Here, we show that SLAMF8 and SLAMF9 co-regulate macrophage-mediated liver inflammation. To overcome the redundancy, we generated mice that simultaneously lacked SLAMF8 and SLAMF9 using CRISPR-Cas9 technology. Although macrophage differentiation was not altered by the combined deficiency of SLAMF8 and SLAMF9, the loss of these two receptors significantly protected against lipopolysaccharide (LPS)-induced liver injury. SLAMF8 and SLAMF9 double-deficient mice had a prolonged survival rate and less infiltration of inflammatory cells. The depletion of macrophages using clodronate liposomes abolished the effects of SLAMF8 and SLAMF9 deficiencies on LPS-induced liver injury, which demonstrates that these receptors are required for macrophage activation following LPS challenge. Moreover, the deficiency of SLAMF8 and SLAMF9 suppressed the secretion of inflammatory cytokines by downregulating the expression of Toll-like receptor-4 (TLR4), a receptor that specifically binds LPS, which led to decreased mitogen-activated protein kinases (MAPK) signaling activation. Notably, combined injections of truncated extracellular SLAMF8 and SLAMF9 proteins significantly alleviated LPS-induced liver injury. Thus, our findings provide insights into the role of SLAMF8 and SLAMF9 in endotoxin-induced liver injury and suggest that SLAMF8 and SLAMF9 are potential therapeutic targets for acute hepatic injury.


Subject(s)
Down-Regulation/genetics , Hepatitis/etiology , Hepatitis/immunology , Lipopolysaccharides/adverse effects , MAP Kinase Signaling System/genetics , Macrophages/immunology , Membrane Proteins/deficiency , Signaling Lymphocytic Activation Molecule Family/deficiency , Toll-Like Receptor 4/metabolism , Animals , CRISPR-Cas Systems , Cell Differentiation/genetics , Cytokines/metabolism , Hepatitis/metabolism , Hepatitis/mortality , Macrophage Activation/genetics , Macrophages/metabolism , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Mitogen-Activated Protein Kinases/metabolism , RAW 264.7 Cells , Signaling Lymphocytic Activation Molecule Family/genetics , Survival Rate , Transfection
2.
Nat Commun ; 7: 12730, 2016 09 07.
Article in English | MEDLINE | ID: mdl-27601261

ABSTRACT

Activation of metabolic signalling by IL-15 is required for natural killer (NK) cell development. Here we show that Tsc1, a repressor of mTOR, is dispensable for the terminal maturation, survival and function of NK cells but is critical to restrict exhaustive proliferation of immature NK cells and activation downstream of IL-15 during NK cell development. Tsc1 is expressed in immature NK cells and is upregulated by IL-15. Haematopoietic-specific deletion of Tsc1 causes a marked decrease in the number of NK cells and compromises rejection of 'missing-self' haematopoietic tumours and allogeneic bone marrow. The residual Tsc1-null NK cells display activated, pro-apoptotic phenotype and elevated mTORC1 activity. Deletion of Raptor, a component of mTORC1, largely reverses these defects. Tsc1-deficient NK cells express increased levels of T-bet and downregulate Eomes and CD122, a subunit of IL-15 receptor. These results reveal a role for Tsc1-dependent inhibition of mTORC1 activation during immature NK cell development.


Subject(s)
Interleukin-15/metabolism , Killer Cells, Natural/physiology , Mechanistic Target of Rapamycin Complex 1/metabolism , Tumor Suppressor Proteins/metabolism , Animals , Apoptosis/physiology , B-Lymphocytes , Gene Expression Regulation/physiology , Hematopoiesis/physiology , Interleukin-15/genetics , Interleukin-2 Receptor beta Subunit/genetics , Interleukin-2 Receptor beta Subunit/metabolism , Mechanistic Target of Rapamycin Complex 1/genetics , Melanoma, Experimental , Mice , Mice, Knockout , Protein Subunits , T-Box Domain Proteins/genetics , T-Box Domain Proteins/metabolism , T-Lymphocytes , Tuberous Sclerosis Complex 1 Protein , Tumor Suppressor Proteins/genetics , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...